Lansoprazole protects hepatic cells against cisplatin-induced oxidative stress through the p38 MAPK/ARE/Nrf2 pathway
Fig 4
Lansoprazole activates p38 MAPK, but not ERK1/2 or JNK in RL34 cells.
A: Detection of phosphorylated Nrf2 in the nucleus. RL34 cells were treated with lansoprazole for 3 h. Nuclear protein extracts from the cells were incubated with or without λPPase at 4°C or 30°C, for 30 min, and were analyzed using immunoblotting with an anti-Nrf2 antibody. B: Representative immunoblot for the phosphorylated and total p38 MAPK, ERK1/2, and JNK expression levels. RL34 cells were treated with 100 μM of lansoprazole for 3 h. Whole cell lysates from the cells were analyzed using immunoblotting with the indicated antibodies; β-actin served as a loading control (left). Densitometric quantification of representative immunoblots was performed using ImageJ. Values were normalized to β-actin protein levels. The ratio of the phosphorylated protein to total protein were also calculated (right). Data represent the mean ± SD of three independent experiments performed in triplicate. Statistical analysis was performed using Student’s t-test. *: p < 0.05 vs. DMSO-treated cells. Abbreviation: LPZ, lansoprazole.